¼¼°èÀÇ µ¶¼º ½ÃÇè ¾Æ¿ô¼Ò½Ì ½ÃÀå
Toxicity Testing Outsourcing
»óǰÄÚµå : 1777629
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 369 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,186,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,559,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ µ¶¼º ½ÃÇè ¾Æ¿ô¼Ò½Ì ½ÃÀåÀº 2030³â±îÁö 56¾ï ´Þ·¯¿¡ µµ´Þ

2024³â¿¡ 36¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ µ¶¼º ½ÃÇè ¾Æ¿ô¼Ò½Ì ½ÃÀåÀº 2024-2030³â¿¡ CAGR 7.5%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 56¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ In-Vitro´Â CAGR 6.0%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 31¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. »ýü³» ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£¿¡ CAGR 9.6%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 9¾ï 8,060¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 11.5%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ µ¶¼º ½ÃÇè ¾Æ¿ô¼Ò½Ì ½ÃÀåÀº 2024³â¿¡ 9¾ï 8,060¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 12¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 11.5%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 3.9%¿Í 7.1%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 5.0%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

µ¶¼º ½ÃÇè ¾Æ¿ô¼Ò½Ì ½ÃÀå µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

µ¶¼º ½ÃÇè ¾Æ¿ô¼Ò½ÌÀÌ ÀǾàǰÀÇ ¾ÈÀü°ú ±ÔÁ¦ Áؼö¸¦ ¾î¶»°Ô °­È­ÇÒ ¼ö Àִ°¡?

µ¶¼º½ÃÇèÀº ½Å¾à, È­Çй°Áú, ¼ÒºñÀç Á¦Ç°ÀÇ ¾ÈÀü¼º°ú À¯È¿¼ºÀ» º¸ÀåÇÏ´Â ÀǾàǰ °³¹ßÀÇ Áß¿äÇÑ ´Ü°èÀÔ´Ï´Ù. µ¶¼º½ÃÇèÀ» Àü¹® CRO(ÀÓ»ó½ÃÇè ¼öʱâ°ü)¿¡ À§Å¹ÇÏ´Â °ÍÀº Á¦¾àȸ»ç ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷¿¡°Ô ºñ¿ë Àý°¨, ¿¬±¸°³¹ß ±â°£ ´ÜÃà, ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°ÇÀ» ±Øº¹ÇÒ ¼ö ÀÖ´Â Àü·«ÀûÀÎ Á¢±Ù ¹æ½ÄÀÔ´Ï´Ù. ¾ÈÀü¼º Æò°¡ ÇÁ·ÎÅäÄÝÀÇ º¹À⼺Àº in vitro ¹× ÄÄÇ»ÅÍ µ¶¼º ½ÃÇèÀÇ ¹ßÀü°ú ÇÔ²² ¿ÜºÎ Àü¹®°¡¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ µ¿¹°½ÇÇèÀ» ´ëüÇÒ ¼ö ÀÖ´Â À±¸®Àû ´ë¾ÈÀ» ã´Â ¿òÁ÷ÀÓÀº Àå±â Ĩ°ú AI¸¦ Ȱ¿ëÇÑ ¿¹Ãø ¸ðµ¨¸µÀÇ °³¹ß·Î À̾îÁ® ½ÃÀåÀ» ´õ¿í º¯È­½Ã۰í ÀÖ½À´Ï´Ù. ±×·¯³ª µ¥ÀÌÅÍ ¹«°á¼º, Ç¥ÁØÈ­, ¿©·¯ °üÇұǿ¡ °ÉÄ£ ±ÔÁ¦ Áؼö¿¡ ´ëÇÑ ¿ì·Á´Â ¿©ÀüÈ÷ °úÁ¦·Î ³²¾ÆÀÖ½À´Ï´Ù. µ¶¼º ½ÃÇèÀÌ ÁøÈ­ÇÏ´Â °¡¿îµ¥, ¾Æ¿ô¼Ò½Ì ÆÄÆ®³Ê½ÊÀº ¾î¶»°Ô Çõ½ÅÀ» ÃËÁøÇϰí Â÷¼¼´ë Ä¡·áÁ¦ÀÇ ¾ÈÀü¼ºÀ» º¸ÀåÇÒ ¼ö Àִ°¡?

¾î¶² ±â¼ú Çõ½ÅÀÌ µ¶¼º ½ÃÇè ¾Æ¿ô¼Ò½ÌÀ» ¹ßÀü½Ã۰í Àִ°¡?

µ¶¼º½ÃÇèÀÇ ÃÖ÷´Ü °³¹ß¿¡´Â AI¸¦ Ȱ¿ëÇÑ µ¶¼º ¿¹Ãø ¸ðµ¨, ÇÏÀ̽º·çDz ½ºÅ©¸®´×(HTS), ÀÎü Àå±â°è¸¦ ¸ð¹æÇÑ 3D ¼¼Æ÷¹è¾ç ¸ðµ¨ µîÀÌ ÀÖ½À´Ï´Ù. ¸Ó½Å·¯´× ¾Ë°í¸®ÁòÀº ¹æ´ëÇÑ µ¥ÀÌÅͼ¼Æ®¸¦ ºÐ¼®ÇÏ¿© ÀǾàǰ °³¹ß Ãʱ⠴ܰ迡¼­ ÀáÀçÀûÀÎ ¾ÈÀü¼º À§ÇèÀ» ½Äº°ÇÔÀ¸·Î½á µ¶¼º Æò°¡¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. ¸¶ÀÌÅ©·ÎÇ÷çÀ̵ñ½º Àå±â Ĩ Ç÷§Æû°ú °°Àº in vitro ½ÃÇè¹ýÀº µ¿¹° ¸ðµ¨¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ³·Ãß´Â µ¿½Ã¿¡ º¸´Ù Àΰ£°ú °ü·ÃµÈ µ¶¼º µ¥ÀÌÅ͸¦ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ ºí·ÏüÀÎ ±â¼úÀº µ¥ÀÌÅÍ ÃßÀû¼º ¹× ±ÔÁ¦ Áؼö¸¦ À§ÇØ °ËÅäµÇ°í ÀÖÀ¸¸ç, Àü ¼¼°è µ¶¼º ½ÃÇè ³×Æ®¿öÅ© ÀüüÀÇ Åõ¸í¼º°ú Ç¥ÁØÈ­¸¦ º¸ÀåÇϰí ÀÖ½À´Ï´Ù.

µ¶¼º ½ÃÇè ¾Æ¿ô¼Ò½Ì¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

ÀǾàǰ ¾ÈÀü¼º¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ °¨½Ã °­È­, ÀǾàǰ °³¹ß ÆÄÀÌÇÁ¶óÀÎÀÇ º¹À⼺ Áõ°¡, ´ëü ½ÃÇè¹ý äÅà Áõ°¡ µîÀÌ µ¶¼º ½ÃÇè ¼­ºñ½º ¾Æ¿ô¼Ò½Ì ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Á¦¾à»çµéÀº ÁøÈ­ÇÏ´Â ¾ÈÀü Ç¥ÁØÀ» ÁؼöÇÒ ¼ö ÀÖ´Â ºñ¿ë È¿À²ÀûÀÎ ¼Ö·ç¼ÇÀ» ¿ì¼±½ÃÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¸ÂÃãÇü ÀÇ·á¿Í »ý¹°Á¦Á¦·ÎÀÇ ÀüȯÀ¸·Î ÀÎÇØ º¸´Ù Àü¹®ÀûÀÎ µ¶¼º Æò°¡°¡ ÇÊ¿äÇØÁö¸é¼­ ¾Æ¿ô¼Ò½ÌÀÇ Ãß¼¼¸¦ ´õ¿í ºÎÃß±â°í ÀÖ½À´Ï´Ù.

µ¶¼º ½ÃÇè ¾Æ¿ô¼Ò½Ì ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

¿¹Ãø µ¶¼ºÇÐÀÇ ¹ßÀü, AI¸¦ Ȱ¿ëÇÑ ¾ÈÀü¼º Æò°¡ ÅøÀÇ Ã¤Åà Ȯ´ë, È­Çй°Áú ¹× ÀǾàǰ ¾ÈÀü¿¡ ´ëÇÑ ±ÔÁ¦ ¿ä°Ç °­È­, ºñ¿ë È¿À²ÀûÀÎ ¾Æ¿ô¼Ò½Ì ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µîÀÌ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. Á¦¾àȸ»çµéÀÌ ¾ö°ÝÇÑ ¾ÈÀü±âÁØÀ» ÃæÁ·½ÃŰ¸é¼­ È¿À²¼ºÀ» ³ôÀ̱â À§ÇØ ³ë·ÂÇÏ´Â °¡¿îµ¥, µ¶¼º½ÃÇè¿¡¼­ CROÀÇ ¿ªÇÒÀº ÀǾàǰ °³¹ß ¹× ±ÔÁ¦ÁؼöÀÇ ¹Ì·¡¸¦ Çü¼ºÇÏ´Â µ¥ ÀÖÀ¸¸ç, Á¡Á¡ ´õ Áß¿äÇØÁú °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ºÎ¹®

½ÃÇè¹ý(in-vitro, in-vivo); GLP À¯Çü(GLP, ºñGLP); ÃÖÁ¾»ç¿ëÀÚ(Á¦¾à¡¤¹ÙÀÌ¿ÀÆÄ¸¶ ±â¾÷, Çмú¡¤¿¬±¸±â°ü, ±âŸ)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

´ç»ç´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Toxicity Testing Outsourcing Market to Reach US$5.6 Billion by 2030

The global market for Toxicity Testing Outsourcing estimated at US$3.6 Billion in the year 2024, is expected to reach US$5.6 Billion by 2030, growing at a CAGR of 7.5% over the analysis period 2024-2030. In-Vitro, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$3.1 Billion by the end of the analysis period. Growth in the In-Vivo segment is estimated at 9.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$980.6 Million While China is Forecast to Grow at 11.5% CAGR

The Toxicity Testing Outsourcing market in the U.S. is estimated at US$980.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 11.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.9% and 7.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Toxicity Testing Outsourcing Market Trends & Drivers Summarized

How Is Outsourcing Toxicity Testing Enhancing Drug Safety and Regulatory Compliance?

Toxicity testing is a critical step in drug development, ensuring the safety and efficacy of new pharmaceuticals, chemicals, and consumer products. Outsourcing toxicity testing to specialized contract research organizations (CROs) has become a strategic approach for pharmaceutical and biotechnology firms, allowing them to reduce costs, accelerate development timelines, and navigate stringent regulatory requirements. The increasing complexity of safety assessment protocols, coupled with advancements in in vitro and computational toxicity testing, is driving demand for external expertise. Additionally, the push for ethical alternatives to animal testing has led to the development of organ-on-a-chip and AI-driven predictive modeling, further transforming the market. However, concerns regarding data integrity, standardization, and regulatory compliance across different jurisdictions remain challenges. As toxicity testing evolves, how will outsourcing partnerships drive innovation and ensure the safety of next-generation therapeutics?

What Technological Innovations Are Advancing Toxicity Testing Outsourcing?

Cutting-edge developments in toxicity testing include AI-powered toxicity prediction models, high-throughput screening (HTS), and 3D cell culture models that mimic human organ systems. Machine learning algorithms are revolutionizing toxicity assessment by analyzing vast datasets and identifying potential safety risks early in drug development. In vitro testing methods, such as microfluidic organ-on-a-chip platforms, are reducing reliance on animal models while providing more human-relevant toxicity data. Additionally, blockchain technology is being explored for data traceability and regulatory compliance, ensuring transparency and standardization across global toxicity testing networks.

Why Is the Demand for Toxicity Testing Outsourcing Increasing?

The growing regulatory scrutiny of pharmaceutical safety, increasing complexity of drug development pipelines, and rising adoption of alternative testing methods are driving demand for outsourced toxicity testing services. Pharmaceutical companies are prioritizing cost-effective solutions that ensure compliance with evolving safety standards. Additionally, the shift toward personalized medicine and biologics is requiring more specialized toxicity evaluation, further boosting outsourcing trends.

What Factors Are Driving the Growth of the Toxicity Testing Outsourcing Market?

The market is expanding due to advancements in predictive toxicology, increasing adoption of AI-driven safety assessment tools, growing regulatory requirements for chemical and pharmaceutical safety, and rising demand for cost-effective outsourcing solutions. As drug developers seek to improve efficiency while meeting strict safety standards, the role of CROs in toxicity testing is expected to become increasingly vital in shaping the future of drug development and regulatory compliance.

SCOPE OF STUDY:

The report analyzes the Toxicity Testing Outsourcing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Method (In-Vitro, In-Vivo); GLP Type (GLP, Non-GLP); End-Use (Pharma & Biopharma Companies, Academic & Research Institutes, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â